XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure        
Pay vs Performance Disclosure, Table
Value of Initial Fixed $100 Investment Based on:
YearSummary Compensation Table Total for PEO (1)Compensation Actually Paid to PEO (2)Average Summary Compensation Table Total for Other NEOs (1)Average Compensation Actually Paid to Other NEOs (2)Cumulative Total Shareholder Return (3)Peer Group Cumulative Total Shareholder Return (4)Net Income (Millions) (5)Company-Selected Measure: Net Revenue (Millions) (6)
2023
$1,521,026$(5,225,762)$5,473,623$(1,202,184)$18$119$(207)$509.338
2022$2,278,951$2,075,757$6,477,346$5,788,737$87$114$(93)$537.840
2021$1,179,283$(31,518,263)$5,653,771$(12,875,003)$89$126$(58)$535.031
2020
$8,956,704$53,324,965$7,398,969$44,401,582$205$126$20$494.366
      
Company Selected Measure Name Net Revenue      
Named Executive Officers, Footnote Mr. Danziger is our PEO for each year represented. The other named executive officers represented in the Other NEO average amounts above are:
• 2023: Ms. Cordova, Mr. Groenhuysen, Mr. Leonard, Mr. Shah and Mr. Ben-Arye
• 2022: Ms. Cordova, Mr. Groenhuysen, Mr. Leonard and Mr. Shah
• 2021: Ms. Cordova, Mr. Groenhuysen, Mr. Longsworth and Mr. Shah
• 2020: Mr. Doyle, Ms. Cordova, Mr. Groenhuysen, Mr. Longsworth and Mr. Shah
      
Peer Group Issuers, Footnote The peer group represented is the NASDAQ Biotechnology Index Index which is the peer group represented in Part II, Item 5, Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities of our Annual Report. The Cumulative TSR for the peer group reflects weighting of each constituent company’s TSR by its stock market capitalization.      
PEO Total Compensation Amount $ 1,521,026 $ 2,278,951 $ 1,179,283 $ 8,956,704
PEO Actually Paid Compensation Amount $ (5,225,762) 2,075,757 (31,518,263) 53,324,965
Adjustment To PEO Compensation, Footnote The following adjustments were made to summary compensation totals to determine the Compensation Actually Paid values to our PEO and the Average Compensation Actually Paid values to our Other NEOs. The Fair Value of Equity Award values were determined using a Black-Scholes option-pricing model. The dollar amounts do not reflect the actual amount of compensation earned by or paid during the applicable year.
2023202220212020
Summary Compensation Table Total for PEO$1,521,026 $2,278,951 $1,179,283 $8,956,704 
Subtract: Grant Date Fair Value of Equity Awards$— $(579,437)$— $(6,946,850)
Add: Year-end Fair Value of Equity Awards Granted in the Applicable Fiscal Year that are Outstanding and Unvested$— $498,330 $— $17,328,572 
Add (Subtract): Year over Year Change in Fair Value of Equity Awards Granted in Prior Fiscal Years that Vested in the Year$(6,801,975)$(186,784)$(31,193,820)$34,084,824 
Add (Subtract): Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards$55,187 $64,697 $(1,503,726)$(98,284)
Add: Value of Dividends on Stock Awards not Otherwise Reflected in Fair Value or Total Compensation$— $— $— $— 
Compensation Actually Paid to PEO$(5,225,762)$2,075,757 $(31,518,263)$53,324,965 
      
Non-PEO NEO Average Total Compensation Amount $ 5,473,623 6,477,346 5,653,771 7,398,969
Non-PEO NEO Average Compensation Actually Paid Amount $ (1,202,184) 5,788,737 (12,875,003) 44,401,582
Adjustment to Non-PEO NEO Compensation Footnote
2023202220212020
Average Summary Compensation Table Total for Other NEOs$5,473,623 $6,477,346 $5,653,771 $7,398,969 
Subtract: Grant Date Fair Value of Equity Awards$(4,661,927)$(5,608,911)$(5,122,931)$(6,125,015)
Add: Year-end Fair Value of Equity Awards Granted in the Applicable Fiscal Year that are Outstanding and Unvested$637,101 $5,003,251 $1,559,370 $16,047,959 
Add (Subtract): Year over Year Change in Fair Value of Equity Awards Granted in Prior Fiscal Years that Vested in the Year$(3,671,596)$(121,327)$(13,778,889)$33,150,418 
Add (Subtract): Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards$1,020,615 $38,378 $(1,186,323)$(6,070,749)
Add: Value of Dividends on Stock Awards not Otherwise Reflected in Fair Value or Total Compensation$— $— $— $— 
Average Compensation Actually Paid to Other NEOs$(1,202,184)$5,788,737 $(12,875,003)$44,401,582 
      
Compensation Actually Paid vs. Total Shareholder Return
The following chart sets forth the relationship between Compensation Actually Paid ("CAP") to our PEO, the average of Compensation Actually Paid to our other NEOs, and our Cumulative TSR over the four most recently completed fiscal years.
The chart below illustrates the mostly positive correlation between Compensation Actually Paid and the TSR of our Ordinary Shares and of the Nasdaq Biotechnology index over the same period. The TSR amounts in the graph assume the investment of $100 on December 31, 2019 and the reinvestment of any dividends paid. This correlation is to be expected due to the significant value equity awards have as a percentage of our NEOs’ total overall compensation packages. This relationship can be seen for both our PEO and our other NEOs as a group most notably in 2020 and 2021. Our PEO has not received significant equity awards since 2020 (see "Long-Term Incentives - 2020 Performance Awards to CEO and Executive Chairman" on page 56).
CAP vs TSR.gif
      
Compensation Actually Paid vs. Net Income
Description of Relationship Between PEO and Other NEO Compensation Actually Paid and Net Income
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our other NEOs, and our Net Income during the four most recently completed fiscal years.
CAP vs Net Income.gif
      
Compensation Actually Paid vs. Company Selected Measure
Description of Relationship Between PEO and Other NEO Compensation Actually Paid and Net Revenue.
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our other NEOs, and our Net Revenue during the four most recently completed fiscal years.
CAP vs Net Revenue.gif
      
Tabular List, Table
Net Revenue
TSR
Adjusted EBITDA
New Patient Starts
Clinical Trial Milestones
      
Total Shareholder Return Amount $ 18 87 89 205
Peer Group Total Shareholder Return Amount 119 114 126 126
Net Income (Loss) $ (207,000,000) $ (93,000,000) $ (58,000,000) $ 20,000,000
Company Selected Measure Amount 509,338,000 537,840,000 535,031,000.000 494,366,000
PEO Name Mr. Danziger      
Additional 402(v) Disclosure Cumulative Total Shareholder Return (“TSR”) represents the price appreciation of our Ordinary Shares plus dividends paid (assuming reinvestment) during the measurement period beginning as of market close December 31, 2019 through December 31 of the year noted.Net Income amounts reported here are the net income amounts reflected in the our audited consolidated financial statements for the applicable years.Net Revenue amounts reported here are the net revenue amounts reflected in the our audited consolidated financial statements for the applicable years.      
Measure:: 1        
Pay vs Performance Disclosure        
Name Net Revenue      
Measure:: 2        
Pay vs Performance Disclosure        
Name TSR      
Measure:: 3        
Pay vs Performance Disclosure        
Name Adjusted EBITDA      
Measure:: 4        
Pay vs Performance Disclosure        
Name New Patient Starts      
Measure:: 5        
Pay vs Performance Disclosure        
Name Clinical Trial Milestones      
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount $ 0 $ (579,437) $ 0 $ (6,946,850)
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0 498,330 0 17,328,572
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 55,187 64,697 (1,503,726) (98,284)
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (6,801,975) (186,784) (31,193,820) 34,084,824
PEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0 0 0 0
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (4,661,927) (5,608,911) (5,122,931) (6,125,015)
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 637,101 5,003,251 1,559,370 16,047,959
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 1,020,615 38,378 (1,186,323) (6,070,749)
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (3,671,596) (121,327) (13,778,889) 33,150,418
Non-PEO NEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount $ 0 $ 0 $ 0 $ 0